Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of GBPD002 and Eprex in Healthy Volunteers
NCT05585658Phase 2Completed
- Sponsor
- Globe Biotech Limited
- Start
- Oct 2021
- Primary completion
- Nov 2021
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of erythropoietin in anemia (2 arms), sponsored by Globe Biotech Limited. Primary endpoints: Maximum Observed Concentration at 144 hours and Area Under the Curve Extrapolated to Infinity at 144 hours. Started Oct 2021; status: completed.
02
Drugs
erythropoietin
03
Conditions
anemia
Beyond the preview
Go deeper on NCT05585658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05585658.